Moderna Inc. (MRNA)
Health Care4 articles
Market Mood
Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
The US FDA announced it will hold a meeting with an expert committee to review the flu vaccine developed by Moderna (MRNA). This meeting is crucial as it will assess the vaccine's efficacy and safety. Given the increasing interest in flu vaccinations, particularly in the context of ongoing health concerns, this evaluation may impact market perception of Moderna's future revenues. The outcome of the review could influence both Moderna's stock performance and broader market trends in the biotech sector.
Read More
Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) is currently under scrutiny regarding its profitability as the company's revenue streams face challenges. The latest reports indicate a significant decrease in demand for its COVID-19 vaccine, leading to a projected revenue drop of 70% for 2023 compared to 2022. Given these developments, experts are closely monitoring MRNA's financial stability and operational adjustments. The ongoing analysis could impact the biotech sector as investors evaluate the company's future prospects.
Read More
Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Several stocks, including Moderna (MRNA), Lumentum, Intel, and monday.com, are experiencing notable movements in premarket trading. However, concrete data points such as trading volumes or percentage changes have not been reported in this article. The market impact of these movements remains unclear due to the lack of specific figures or insights into the reasons behind the fluctuations. Monitoring these stocks could provide insights into broader market trends and investor sentiment.
Read More
Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Following the World Health Organization's announcement of a hantavirus outbreak on May 2, several pharmaceutical stocks, including Moderna (MRNA), experienced significant gains. Moderna's shares increased by 7% in premarket trading as the company is conducting preclinical research on the hantavirus. Inovio Pharmaceuticals reported a 13% rise, while Emergent Biosolutions and Novavax gained 4% and 3%, respectively. Analysts from Evercore ISI suggested that any revenue potential for Moderna related to hantavirus is unlikely, viewing stock movements as sentiment-driven rather than fundamentally driven.
Read More